DTIL
PRECISION BIOSCIENCES INC
Company overview
- Market capitalization
- $172.23M
- Employees
- 66
- Latest publication
- 2026-09-29
About PRECISION BIOSCIENCES INC
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Financial statements
Income Quarterly
| Metric | Q2 20262026-06-30 · USD | Q1 20262026-03-31 · USD | Q4 20252025-12-31 · USD | Q3 20252025-09-30 · USD | Q2 20252025-06-30 · USD | Q1 20252025-03-31 · USD | Q4 20242024-12-31 · USD | Q4 20232023-12-31 · USD |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0USD | 10,838,000USD | 34,204,000USD | 13,000USD | 18,000USD | 29,000USD | 638,000USD | 7,038,000USD |
| Research Development | 12,394,000USD | 13,110,000USD | 14,464,000USD | 13,352,000USD | 12,768,000USD | 13,588,000USD | 15,907,000USD | 13,389,000USD |
| General And Administrative Expenses | 6,767,000USD | — | — | — | — | — | — | — |
| Total Operating Expenses | 19,161,000USD | 19,913,000USD | 21,696,000USD | 20,680,000USD | 21,895,000USD | 22,141,000USD | 25,484,000USD | 21,928,000USD |
| Operating Income | -19,161,000USD | -9,075,000USD | 12,508,000USD | -20,667,000USD | -21,877,000USD | -22,112,000USD | -24,846,000USD | -14,890,000USD |
| Total Other Income Expense Net | -13,491,000USD | -9,366,000USD | 6,740,000USD | -1,105,000USD | -1,643,000USD | 1,547,000USD | 7,101,000USD | 1,456,000USD |
| Interest Expense | 300,000USD | 311,000USD | 348,000USD | 362,000USD | 358,000USD | 354,000USD | 392,000USD | 579,000USD |
| Equity Method Income Loss | 0USD | — | — | — | — | — | — | — |
| Net Income | -32,652,000USD | -18,441,000USD | 20,133,000USD | -21,772,000USD | -23,520,000USD | -20,565,000USD | -17,745,000USD | -16,289,000USD |
| Gross Profit | — | 10,838,000USD | 34,204,000USD | 13,000USD | 18,000USD | 29,000USD | 638,000USD | 7,038,000USD |
| Selling General Administrative | — | 6,803,000USD | 7,232,000USD | 7,328,000USD | 9,127,000USD | 8,553,000USD | 9,577,000USD | 8,539,000USD |
| Interest Income | — | 999,000USD | 773,000USD | 1,027,000USD | 1,116,000USD | 1,323,000USD | 1,494,000USD | 1,827,000USD |
| Net Interest Income | — | 688,000USD | 425,000USD | 665,000USD | 758,000USD | 969,000USD | 1,102,000USD | 1,248,000USD |
| Income Before Tax | — | -18,441,000USD | 19,248,000USD | -21,772,000USD | -23,520,000USD | -20,565,000USD | -17,745,000USD | -13,434,000USD |
| Net Income From Continuing Ops | — | -18,441,000USD | 19,248,000USD | -21,772,000USD | -23,520,000USD | -20,565,000USD | -17,745,000USD | -13,434,000USD |
| Ebit | — | -18,130,000USD | 19,596,000USD | -21,410,000USD | -23,162,000USD | -20,211,000USD | -17,353,000USD | -12,855,000USD |
| Ebitda | — | -17,490,000USD | 20,274,000USD | -20,736,000USD | -22,466,000USD | -19,506,000USD | -16,596,000USD | -11,299,000USD |
| Depreciation And Amortization | — | 640,000USD | 678,000USD | 674,000USD | 696,000USD | 705,000USD | 757,000USD | 1,556,000USD |
| Reconciled Depreciation | — | 640,000USD | 678,000USD | 674,000USD | 696,000USD | 705,000USD | 757,000USD | 1,556,000USD |
| Cost Of Revenue | — | — | 678,000USD | 674,000USD | 696,000USD | — | 757,000USD | 1,556,000USD |
| Income Tax Expense | — | — | — | — | — | — | -1,724USD | 2,855,000USD |
| Selling And Marketing Expenses | — | — | — | — | — | — | — | 592,000USD |
| Source | DisclosureDeterministicFinal | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy |
Income Yearly
| Metric | FY 20252025-12-31 · USD | FY 20242024-12-31 · USD | FY 20212021-12-31 · USD | FY 20172017-12-31 · USD | FY 20162016-12-31 · USD |
|---|---|---|---|---|---|
| Total Revenue | 34,264,000USD | 68,696,000USD | 115,529,000USD | 6,484,000USD | 7,015,000USD |
| Cost Of Revenue | 2,753,000USD | 4,577,000USD | — | 0USD | 0USD |
| Gross Profit | 34,264,000USD | 68,696,000USD | 115,529,000USD | 6,484,000USD | 7,015,000USD |
| Research Development | 54,172,000USD | 59,559,000USD | 115,238,000USD | 20,324,000USD | 9,102,000USD |
| Selling General Administrative | 32,240,000USD | 35,299,000USD | 39,667,000USD | 8,016,000USD | 6,168,000USD |
| Total Operating Expenses | 86,412,000USD | 94,858,000USD | 154,905,000USD | 28,340,000USD | 15,203,000USD |
| Operating Income | -52,148,000USD | -26,162,000USD | -39,376,000USD | -21,974,000USD | -8,828,000USD |
| Interest Income | 4,239,000USD | 6,763,000USD | 208,000USD | 872,000USD | 570,000USD |
| Interest Expense | 1,422,000USD | 1,782,000USD | 132,000USD | 0USD | 0USD |
| Net Interest Income | 2,817,000USD | 4,981,000USD | 76,000USD | 872,000USD | — |
| Income Before Tax | -46,609,000USD | 7,167,000USD | -30,602,000USD | -21,102,000USD | -8,256,000USD |
| Net Income | -45,724,000USD | 7,167,000USD | -30,602,000USD | -21,102,000USD | -8,251,000USD |
| Net Income From Continuing Ops | -46,609,000USD | 7,167,000USD | -30,602,000USD | -21,102,000USD | -8,251,000USD |
| Ebit | -45,187,000USD | 8,949,000USD | -30,470,000USD | -21,856,000USD | -8,828,000USD |
| Ebitda | -42,434,000USD | 13,526,000USD | -20,273,000USD | -20,421,000USD | -8,188,000USD |
| Depreciation And Amortization | 2,753,000USD | 4,577,000USD | 10,197,000USD | 1,435,000USD | 640,000USD |
| Reconciled Depreciation | 2,753,000USD | 4,577,000USD | 10,197,000USD | 1,435,000USD | — |
| Total Other Income Expense Net | 5,539,000USD | 33,329,000USD | 8,774,000USD | 872,000USD | 572,000USD |
| Income Tax Expense | — | — | 316,000USD | -754,000USD | -5,000USD |
| Non Operating Income Net Other | — | — | 8,800,000USD | — | — |
| Net Income Applicable To Common Shares | — | — | -30,602,000USD | -21,102,000USD | -8,251,000USD |
| Tax Provision | — | — | — | — | -5,000USD |
| Source | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy |
Balance sheet Quarterly
| Metric | Q2 20262026-06-30 · USD | Q1 20262026-03-31 · USD | Q4 20252025-12-31 · USD | Q3 20252025-09-30 · USD | Q2 20252025-06-30 · USD | Q1 20252025-03-31 · USD | Q4 20242024-12-31 · USD | Q3 20242024-09-30 · USD |
|---|---|---|---|---|---|---|---|---|
| Total Assets | 125,920,000USD | 143,891,000USD | 154,416,000USD | 93,510,000USD | 108,928,000USD | 124,411,000USD | 136,388,000USD | 153,258,000USD |
| Cash And Equivalents | 86,076,000USD | — | — | — | — | — | — | — |
| Cash And Short Term Investments | 87,549,000USD | 101,184,000USD | 115,585,000USD | 44,870,000USD | 62,242,000USD | 77,223,000USD | 86,312,000USD | 101,202,000USD |
| Short Term Investments | 1,473,000USD | 1,814,000USD | 4,762,000USD | 0USD | 0USD | 0USD | 413,000USD | 2,450,000USD |
| Total Current Assets | 91,549,000USD | 108,693,000USD | 118,740,000USD | 51,705,000USD | 70,259,000USD | 82,103,000USD | 94,989,000USD | 110,523,000USD |
| Other Current Assets | 5,000USD | 3,509,000USD | 3,155,000USD | 6,831,000USD | 8,017,000USD | 4,876,000USD | 6,979,000USD | 7,774,000USD |
| Other Non Current Assets | 126,000USD | — | — | — | — | — | — | — |
| Total Liabilities | 80,627,000USD | — | — | — | — | — | — | — |
| Total Current Liabilities | 7,140,000USD | 7,755,000USD | 8,913,000USD | 14,996,000USD | 13,568,000USD | 12,393,000USD | 14,980,000USD | 11,982,000USD |
| Other Current Liabilities | 588,000USD | — | — | — | — | — | — | — |
| Other Non Current Liabilities | 301,000USD | — | — | — | — | — | — | — |
| Total Stockholder Equity | 45,293,000USD | 76,101,000USD | 92,248,000USD | 16,634,000USD | 34,054,000USD | 49,337,000USD | 56,393,000USD | 64,866,000USD |
| Total Equity Including Noncontrolling Interest | 45,293,000USD | — | — | — | — | — | — | — |
| Net Receivables | 0USD | 4,000,000USD | 0USD | 4,000USD | 5,730,000USD | 4,000USD | 1,698,000USD | 1,547,000USD |
| Property Plant Equipment Net | 6,078,000USD | 6,647,000USD | 7,230,000USD | 8,164,000USD | 8,818,000USD | 9,497,000USD | 10,179,000USD | 10,956,000USD |
| Intangible Assets | 1,093,000USD | 1,127,000USD | 1,166,000USD | 985,000USD | 605,000USD | 607,000USD | 622,000USD | 388,000USD |
| Accounts Payable | 828,000USD | 944,000USD | 296,000USD | 1,340,000USD | 1,121,000USD | 924,000USD | 1,312,000USD | 958,000USD |
| Short Term Debt | 1,608,000USD | 1,557,000USD | 1,507,000USD | 2,916,000USD | 1,411,000USD | 1,365,000USD | 1,320,000USD | 1,275,000USD |
| Common Stock | 1,000USD | 1,000USD | 1,000USD | 1,000USD | 1,000USD | 1,000USD | 1,000USD | 1,000USD |
| Retained Earnings | -579,281,000USD | -546,629,000USD | -528,188,000USD | -548,321,000USD | -526,549,000USD | -503,029,000USD | -482,464,000USD | -464,719,000USD |
| Total Liab | — | 67,790,000USD | 62,168,000USD | 76,876,000USD | 74,874,000USD | 75,074,000USD | 79,995,000USD | 88,392,000USD |
| Other Current Liab | — | 5,254,000USD | 7,110,000USD | 5,950,000USD | 5,047,000USD | 4,373,000USD | 9,391,000USD | 9,574,000USD |
| Capital Stock | — | 0USD | 1,000USD | 1,000USD | 1,000USD | 1,000USD | 1,000USD | 1,000USD |
| Other Assets | — | 1USD | — | — | — | — | — | — |
| Cash | — | 99,370,000USD | 110,823,000USD | 44,870,000USD | 62,242,000USD | 77,223,000USD | 85,899,000USD | 98,752,000USD |
| Net Debt | — | -70,904,000USD | -82,015,000USD | -15,742,000USD | -32,797,000USD | -47,475,000USD | -55,854,000USD | -68,445,000USD |
| Short Long Term Debt Total | — | 28,466,000USD | 28,808,000USD | 29,128,000USD | 29,445,000USD | 29,748,000USD | 30,045,000USD | 30,307,000USD |
| Common Stock Shares Outstanding | — | 24,634,443shares | 19,171,669shares | 11,818,145shares | 11,046,401shares | 8,965,156shares | 6,883,911shares | 7,287,173shares |
| Non Current Assets Total | — | 35,197,999USD | 35,676,000USD | 41,805,000USD | 38,669,000USD | 42,308,000USD | 41,399,000USD | 42,735,000USD |
| Non Current Liabilities Total | — | 60,035,000USD | 53,255,000USD | 61,880,000USD | 61,306,000USD | 62,681,000USD | 65,015,000USD | 76,410,000USD |
| Non Current Liabilities Other | — | 60,035,000USD | 259,000USD | 227,000USD | 200,000USD | 197,000USD | 194,000USD | 188,000USD |
| Non Currrent Assets Other | — | 202,999USD | 26,536,000USD | 200,000USD | 28,502,000USD | 28,998,000USD | 27,392,000USD | 28,185,000USD |
| Net Working Capital | — | 100,938,000USD | 109,827,000USD | 36,709,000USD | 56,691,000USD | 69,710,000USD | 80,009,000USD | 98,541,000USD |
| Unclassified Non Current Assets | — | 27,220,999USD | — | 31,712,000USD | — | — | — | — |
| Unclassified Equity | — | 622,729,000USD | 620,434,000USD | 564,953,000USD | 560,601,000USD | 552,364,000USD | 538,855,000USD | 529,583,000USD |
| Long Term Debt | — | — | 22,404,000USD | 22,374,000USD | 22,354,000USD | 22,337,000USD | 22,321,000USD | 22,278,000USD |
| Long Term Investments | — | — | 744,000USD | 744,000USD | 744,000USD | 3,206,000USD | 3,206,000USD | 3,206,000USD |
| Property Plant Equipment Gross | — | — | 35,922,000USD | 8,164,000USD | 8,818,000USD | 9,497,000USD | 38,255,000USD | 10,956,000USD |
| Unclassified Non Current Liabilities | — | — | 30,592,000USD | 39,279,000USD | 38,752,000USD | 40,147,000USD | 42,500,000USD | 53,944,000USD |
| Current Deferred Revenue | — | — | — | 6,248,000USD | 5,989,000USD | 5,731,000USD | 2,957,000USD | 175,000USD |
| Unclassified Current Liabilities | — | — | — | -1,458,000USD | — | — | — | — |
| Good Will | — | — | — | — | 605,000USD | 607,000USD | — | — |
| Unclassified Current Assets | — | — | — | — | -5,730,000USD | — | — | — |
| Source | DisclosureDeterministicFinal | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy |
Balance sheet Yearly
| Metric | FY 20252025-12-31 · USD | FY 20242024-12-31 · USD | FY 20232023-12-31 · USD | FY 20222022-12-31 · USD | FY 20212021-12-31 · USD | FY 20202020-12-31 · USD | FY 20192019-12-31 · USD | FY 20182018-12-31 · USD |
|---|---|---|---|---|---|---|---|---|
| Total Assets | 154,416,000USD | 136,388,000USD | 159,781,000USD | 238,169,000USD | 211,498,000USD | 150,158,000USD | 235,233,000USD | 138,600,000USD |
| Intangible Assets | 1,166,000USD | 622,000USD | 400,000USD | 731,000USD | 2,048,000USD | 1,373,000USD | 1,432,000USD | 1,466,000USD |
| Other Current Assets | 3,155,000USD | 6,979,000USD | 6,883,000USD | 8,809,000USD | 17,603,000USD | 5,766,000USD | 11,821,000USD | 11,959,000USD |
| Total Liab | 62,168,000USD | 79,995,000USD | 140,920,000USD | 177,736,000USD | 120,330,000USD | 105,733,000USD | 96,919,000USD | 98,640,000USD |
| Total Stockholder Equity | 92,248,000USD | 56,393,000USD | 18,861,000USD | 60,433,000USD | 91,168,000USD | 44,425,000USD | 138,314,000USD | 39,960,000USD |
| Other Current Liab | 7,110,000USD | 9,391,000USD | 11,439,000USD | 11,141,000USD | 11,770,000USD | 9,868,000USD | 8,409,000USD | 3,421,000USD |
| Common Stock | 1,000USD | 1,000USD | 1,000USD | 1,000USD | — | — | — | — |
| Capital Stock | 1,000USD | 1,000USD | 1,000USD | 1,000USD | 0USD | 0USD | 0USD | 0USD |
| Retained Earnings | -528,188,000USD | -482,464,000USD | -489,631,000USD | -428,312,000USD | -316,675,000USD | -286,073,000USD | -177,067,000USD | -85,187,000USD |
| Cash | 110,823,000USD | 85,899,000USD | 116,678,000USD | 189,576,000USD | 143,663,000USD | 89,798,000USD | 180,886,000USD | 103,193,000USD |
| Cash And Short Term Investments | 115,585,000USD | 86,312,000USD | 116,678,000USD | 189,576,000USD | 143,663,000USD | 89,798,000USD | 180,886,000USD | 103,193,000USD |
| Total Current Assets | 118,740,000USD | 94,989,000USD | 136,359,000USD | 199,105,000USD | 161,754,000USD | 105,564,000USD | 193,672,000USD | 115,675,000USD |
| Total Current Liabilities | 8,913,000USD | 14,980,000USD | 49,987,000USD | 59,664,000USD | 35,980,000USD | 42,829,000USD | 26,932,000USD | 14,075,000USD |
| Net Debt | -82,015,000USD | -55,854,000USD | -85,410,000USD | -164,616,000USD | -134,550,000USD | -79,279,000USD | -180,886,000USD | -103,193,000USD |
| Short Term Debt | 1,507,000USD | 1,320,000USD | 23,545,000USD | 1,678,000USD | 1,822,000USD | 1,933,000USD | 6,825,000USD | 3,251,000USD |
| Short Long Term Debt Total | 28,808,000USD | 30,045,000USD | 31,268,000USD | 24,960,000USD | 9,113,000USD | 10,519,000USD | — | — |
| Long Term Debt | 22,404,000USD | 22,321,000USD | — | 22,223,000USD | 2,478,000USD | — | — | — |
| Long Term Investments | 744,000USD | 3,206,000USD | 3,206,000USD | 9,406,000USD | 10,630,000USD | 0USD | — | — |
| Short Term Investments | 4,762,000USD | 413,000USD | 0USD | — | — | — | — | — |
| Net Receivables | 0USD | 1,698,000USD | 12,798,000USD | 720,000USD | 488,000USD | 10,000,000USD | 965,000USD | 523,000USD |
| Accounts Payable | 296,000USD | 1,312,000USD | 2,968,000USD | 653,000USD | 1,144,000USD | 792,000USD | 2,037,000USD | 2,218,000USD |
| Property Plant Equipment Net | 7,230,000USD | 10,179,000USD | 14,601,000USD | 13,779,000USD | 29,334,000USD | 41,500,000USD | 39,571,000USD | 21,147,000USD |
| Property Plant Equipment Gross | 35,922,000USD | 38,255,000USD | 40,089,000USD | 54,252,000USD | 53,248,000USD | 41,500,000USD | 39,571,000USD | 21,147,000USD |
| Common Stock Shares Outstanding | 12,826,078shares | 6,883,911shares | 3,841,405shares | 2,929,949shares | 1,956,270shares | 1,734,391shares | 1,400,000shares | 1,634,341shares |
| Non Current Assets Total | 35,676,000USD | 41,399,000USD | 23,422,000USD | 39,064,000USD | 49,744,000USD | 44,594,000USD | 41,561,000USD | 22,925,000USD |
| Non Current Liabilities Total | 53,255,000USD | 65,015,000USD | 90,933,000USD | 118,072,000USD | 84,350,000USD | 62,904,000USD | 69,987,000USD | 84,565,000USD |
| Non Current Liabilities Other | 259,000USD | 194,000USD | 128,000USD | 95,849,000USD | 81,872,000USD | 392,000USD | — | — |
| Non Currrent Assets Other | 26,536,000USD | 27,392,000USD | 5,215,000USD | 19,806,000USD | 11,520,000USD | 1,721,000USD | 558,000USD | 312,000USD |
| Net Working Capital | 109,827,000USD | 80,009,000USD | 86,372,000USD | 139,441,000USD | 125,774,000USD | 62,735,000USD | 166,740,000USD | 101,600,000USD |
| Unclassified Non Current Liabilities | 30,592,000USD | 42,500,000USD | 90,805,000USD | -93,073,000USD | -77,059,000USD | 8,194,000USD | — | — |
| Unclassified Equity | 620,434,000USD | 538,855,000USD | 508,490,000USD | 489,695,000USD | 408,795,000USD | 331,450,000USD | 326,982,000USD | 131,583,000USD |
| Current Deferred Revenue | — | 2,957,000USD | 12,035,000USD | 46,192,000USD | 21,244,000USD | 30,236,000USD | 16,486,000USD | 8,436,000USD |
| Other Assets | — | — | 1USD | 9,804,000USD | 11,520,000USD | 8,131,000USD | 558,000USD | 312,000USD |
| Short Long Term Debt | — | — | 22,412,000USD | — | — | — | — | — |
| Unclassified Current Liabilities | — | — | -22,412,000USD | — | — | — | -6,825,000USD | -3,251,000USD |
| Other Liab | — | — | — | 93,073,000USD | 77,059,000USD | 54,318,000USD | 69,987,000USD | 84,565,000USD |
| Inventory | — | — | — | 7,552,000USD | 17,434,000USD | 5,762,000USD | 9,497,000USD | — |
| Treasury Stock | — | — | — | -952,000USD | -952,000USD | -952,000USD | -952,000USD | -952,000USD |
| Net Tangible Assets | — | — | — | 59,085,000USD | 89,120,000USD | 43,052,000USD | 136,882,000USD | 38,489,000USD |
| Unclassified Current Assets | — | — | — | -7,552,000USD | -17,434,000USD | -5,762,000USD | -9,497,000USD | — |
| Unclassified Non Current Assets | — | — | — | -14,462,000USD | -15,308,000USD | -8,131,000USD | — | — |
| Accumulated Other Comprehensive Income | — | — | — | — | — | — | -10,649,000USD | -5,484,000USD |
| Source | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy |
Cash flow Quarterly
| Metric | Q1 20262026-03-31 · USD | Q4 20252025-12-31 · USD | Q3 20252025-09-30 · USD | Q2 20252025-06-30 · USD | Q1 20252025-03-31 · USD | Q4 20242024-12-31 · USD | Q3 20242024-09-30 · USD | Q2 20242024-06-30 · USD |
|---|---|---|---|---|---|---|---|---|
| Net Income | -18,441,000USD | 20,133,000USD | -21,772,000USD | -23,520,000USD | -20,565,000USD | -17,745,000USD | -16,425,000USD | 32,749,000USD |
| Depreciation | 640,000USD | 678,000USD | 674,000USD | 696,000USD | 705,000USD | 757,000USD | 1,011,000USD | 1,382,000USD |
| Stock Based Compensation | 1,549,000USD | 2,041,000USD | 2,386,000USD | 2,937,000USD | 2,822,000USD | 3,571,000USD | 3,199,000USD | 2,928,000USD |
| Other Non Cash Items | 10,171,000USD | -11,889,000USD | 1,557,000USD | 2,237,000USD | -719,000USD | -6,167,000USD | -3,596,000USD | -7,458,000USD |
| Change To Account Receivables | -4,000,000USD | -1,465,000USD | -4,000USD | 4,000USD | 1,694,000USD | -151,000USD | 9,769,000USD | 183,000USD |
| Change In Working Capital | -5,856,000USD | -22,213,000USD | 1,885,000USD | -2,621,000USD | -1,295,000USD | 901,000USD | 9,899,000USD | -44,470,000USD |
| Total Cash From Operating Activities | -11,937,000USD | -11,250,000USD | -15,270,000USD | -20,271,000USD | -19,052,000USD | -18,683,000USD | -5,912,000USD | -14,869,000USD |
| Capital Expenditures | -18,000USD | -34,000USD | -15,000USD | -2,000USD | -314,000USD | -97,000USD | -64,000USD | -28,000USD |
| Free Cash Flow | -11,955,000USD | -11,284,000USD | -15,270,000USD | -20,273,000USD | -19,366,000USD | -18,780,000USD | -5,976,000USD | -14,897,000USD |
| Total Cashflows From Investing Activities | -114,000USD | -325,000USD | 17,000USD | -12,000USD | -314,000USD | -97,000USD | -64,000USD | -28,000USD |
| Total Cash From Financing Activities | 745,000USD | 77,516,000USD | 1,659,000USD | 5,300,000USD | 10,687,000USD | 5,920,000USD | 3,733,000USD | 702,000USD |
| Issuance Of Capital Stock | 662,000USD | 77,516,000USD | 1,581,000USD | 5,300,000USD | 1,031,000USD | 5,940,000USD | 3,613,000USD | 702,000USD |
| Change In Cash | -11,306,000USD | 65,941,000USD | -17,372,000USD | -14,981,000USD | -8,679,000USD | -12,860,000USD | -2,243,000USD | -14,195,000USD |
| Begin Period Cash Flow | 137,153,000USD | 71,212,000USD | 62,242,000USD | 77,223,000USD | 108,468,000USD | 121,328,000USD | 123,571,000USD | 137,766,000USD |
| End Period Cash Flow | 125,847,000USD | 137,153,000USD | 44,870,000USD | 62,242,000USD | 99,789,000USD | 108,468,000USD | 121,328,000USD | 123,571,000USD |
| Other Cashflows From Investing Activities | -96,000USD | -296,000USD | 7,000USD | — | -250,000USD | — | -25,000USD | — |
| Other Cashflows From Financing Activities | 745,000USD | 77,516,000USD | 1,659,000USD | — | 140,000USD | 137,000USD | 120,000USD | -28,000USD |
| Net Borrowings | — | 0USD | — | — | — | -20,000USD | — | — |
| Unclassified Financing Cash Flow | — | -77,516,000USD | -1,581,000USD | — | 9,516,000USD | — | — | — |
| Investments | — | — | 17,000USD | -12,000USD | -314,000USD | -97,000USD | -64,000USD | -28,000USD |
| Source | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy |
Cash flow Yearly
| Metric | FY 20252025-12-31 · USD | FY 20242024-12-31 · USD | FY 20232023-12-31 · USD | FY 20222022-12-31 · USD | FY 20212021-12-31 · USD | FY 20202020-12-31 · USD | FY 20192019-12-31 · USD | FY 20182018-12-31 · USD |
|---|---|---|---|---|---|---|---|---|
| Net Income | -45,724,000USD | 7,167,000USD | -61,319,000USD | -111,637,000USD | -30,602,000USD | -109,006,000USD | -92,877,000USD | -46,037,000USD |
| Depreciation | 2,753,000USD | 4,577,000USD | 8,255,000USD | 9,004,000USD | 10,197,000USD | 9,813,000USD | 5,317,000USD | 2,354,000USD |
| Stock Based Compensation | 10,186,000USD | 12,604,000USD | 14,040,000USD | 19,197,000USD | 16,514,000USD | 13,786,000USD | 8,940,000USD | 2,453,000USD |
| Other Non Cash Items | -8,350,000USD | -28,794,000USD | -3,603,000USD | 13,573,000USD | -26,546,000USD | 35,000USD | 16,280,000USD | 14,000USD |
| Change To Account Receivables | 229,000USD | 10,422,000USD | -181,000USD | -232,000USD | 9,512,000USD | -9,035,000USD | -441,000USD | -523,000USD |
| Change In Working Capital | -24,708,000USD | -53,999,000USD | -41,487,000USD | 24,110,000USD | 19,584,000USD | -2,014,000USD | -2,357,000USD | -10,507,000USD |
| Total Cash From Operating Activities | -65,843,000USD | -58,445,000USD | -84,114,000USD | -45,753,000USD | -10,853,000USD | -87,386,000USD | -73,637,000USD | -51,723,000USD |
| Capital Expenditures | -85,000USD | -250,000USD | -2,278,000USD | -3,319,000USD | -5,803,000USD | -5,031,000USD | -24,666,000USD | -15,678,000USD |
| Free Cash Flow | -65,928,000USD | -58,695,000USD | -86,392,000USD | -49,072,000USD | -16,656,000USD | -92,417,000USD | -98,303,000USD | -67,401,000USD |
| Total Cashflows From Investing Activities | -634,000USD | -215,000USD | 5,829,000USD | -3,319,000USD | -5,803,000USD | -5,031,000USD | -24,666,000USD | -15,663,000USD |
| Net Borrowings | 0USD | -37,000USD | 0USD | 19,805,000USD | -48,000USD | 2,470,000USD | 39,550,000USD | 39,550,000USD |
| Total Cash From Financing Activities | 95,162,000USD | 50,450,000USD | 5,387,000USD | 94,985,000USD | 70,521,000USD | 1,329,000USD | 175,996,000USD | 107,777,000USD |
| Issuance Of Capital Stock | 94,944,000USD | 50,238,000USD | 2,159,000USD | 74,345,000USD | 60,477,000USD | 35,000,000USD | 135,185,000USD | 109,742,000USD |
| Change In Cash | 28,685,000USD | -8,210,000USD | -72,898,000USD | 45,913,000USD | 53,865,000USD | -91,088,000USD | 77,693,000USD | 40,391,000USD |
| Begin Period Cash Flow | 108,468,000USD | 116,678,000USD | 189,576,000USD | 143,663,000USD | 89,798,000USD | 180,886,000USD | 103,193,000USD | 62,802,000USD |
| End Period Cash Flow | 137,153,000USD | 108,468,000USD | 116,678,000USD | 189,576,000USD | 143,663,000USD | 89,798,000USD | 180,886,000USD | 103,193,000USD |
| Other Cashflows From Investing Activities | -549,000USD | -25,000USD | 107,000USD | -3,319,000USD | -750,000USD | — | — | 15,000USD |
| Other Cashflows From Financing Activities | 95,162,000USD | 249,000USD | 401,000USD | 835,000USD | 7,574,000USD | 1,329,000USD | -1,361,000USD | 107,777,000USD |
| Unclassified Financing Cash Flow | -94,944,000USD | — | 2,827,000USD | — | -4,265,000USD | -3,159,000USD | — | -39,550,000USD |
| Investments | — | -215,000USD | 5,155,000USD | -3,319,000USD | -5,803,000USD | -5,031,000USD | -24,666,000USD | -15,663,000USD |
| Unclassified Investing Cash Flow | — | — | 2,845,000USD | 6,638,000USD | 6,553,000USD | 5,031,000USD | 24,666,000USD | 15,663,000USD |
| Change To Liabilities | — | — | — | 153,000USD | 867,000USD | 326,000USD | -7,199,000USD | -3,850,000USD |
| Sale Purchase Of Stock | — | — | — | 74,737,000USD | 67,260,000USD | 689,000USD | 136,446,000USD | 0USD |
| Cash And Cash Equivalents Changes | — | — | — | 45,913,000USD | 53,865,000USD | -91,088,000USD | — | — |
| Change To Inventory | — | — | — | — | 4,305,000USD | 8,013,000USD | 5,283,000USD | -5,946,000USD |
| Unclassified Operating Cash Flow | — | — | — | — | — | — | -8,940,000USD | — |
| Source | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy |
Operating metrics
No operating metrics are currently published for this company.
Revenue breakdown
| Period | Dimension | Business / region | Revenue | Currency | Source |
|---|---|---|---|---|---|
| Q2 2024Quarterly · 2024-06-30 | Product | Collaboration And License | 800,000 | USD | 0001628280-25-038594 |
| Q2 2024Quarterly · 2024-06-30 | Product | Development And License | 48,200,000 | USD | 0001628280-25-038594 |
| Q2 2024Quarterly · 2024-06-30 | Product | License | 900,000 | USD | 0001628280-25-038594 |
| Q4 2021Quarterly · 2021-12-31 | Segment | Food | 977,000 | USD | Legacy provider |
| Q4 2021Quarterly · 2021-12-31 | Segment | Therapeutics | 5,362,000 | USD | Legacy provider |
| FY 2021Yearly · 2021-12-31 | Segment | Food | 3,806,000 | USD | 0001564590-22-010222 |
| FY 2021Yearly · 2021-12-31 | Segment | Therapeutics | 111,723,000 | USD | 0001564590-22-010222 |
| Q3 2021Quarterly · 2021-09-30 | Segment | Food | 1,241,000 | USD | 0001564590-21-055930 |
| Q3 2021Quarterly · 2021-09-30 | Segment | Therapeutics | 22,795,000 | USD | 0001564590-21-055930 |
| Q2 2021Quarterly · 2021-06-30 | Segment | Food | 918,000 | USD | 0001564590-21-043680 |
| Q2 2021Quarterly · 2021-06-30 | Segment | Therapeutics | 67,887,000 | USD | 0001564590-21-043680 |
| Q1 2021Quarterly · 2021-03-31 | Segment | Food | 670,000 | USD | 0001564590-21-027213 |
| Q1 2021Quarterly · 2021-03-31 | Segment | Therapeutics | 15,679,000 | USD | 0001564590-21-027213 |
| Q4 2020Quarterly · 2020-12-31 | Segment | Food | 524,000 | USD | Legacy provider |
| Q4 2020Quarterly · 2020-12-31 | Segment | Therapeutics | 8,322,000 | USD | Legacy provider |
| FY 2020Yearly · 2020-12-31 | Segment | Food | 2,422,000 | USD | 0001564590-22-010222 |
| FY 2020Yearly · 2020-12-31 | Segment | Therapeutics | 21,863,000 | USD | 0001564590-22-010222 |
| Q3 2020Quarterly · 2020-09-30 | Segment | Food | 315,000 | USD | 0001564590-21-055930 |
| Q3 2020Quarterly · 2020-09-30 | Segment | Therapeutics | 7,048,000 | USD | 0001564590-21-055930 |
| Q2 2020Quarterly · 2020-06-30 | Segment | Food | 58,000 | USD | 0001564590-21-043680 |
| Q2 2020Quarterly · 2020-06-30 | Segment | Therapeutics | 1,020,000 | USD | 0001564590-21-043680 |
| Q1 2020Quarterly · 2020-03-31 | Segment | Food | 1,525,000 | USD | 0001564590-21-027213 |
| Q1 2020Quarterly · 2020-03-31 | Segment | Therapeutics | 5,473,000 | USD | 0001564590-21-027213 |
| FY 2019Yearly · 2019-12-31 | Segment | Food | 1,606,000 | USD | 0001564590-21-014005 |
| FY 2019Yearly · 2019-12-31 | Segment | Therapeutics | 20,632,000 | USD | 0001564590-21-014005 |
| FY 2018Yearly · 2018-12-31 | Segment | Food | 1,360,000 | USD | 0001564590-20-009541 |
| FY 2018Yearly · 2018-12-31 | Segment | Therapeutics | 9,523,000 | USD | 0001564590-20-009541 |
Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.